Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus

Yanjin Hu(Capital Medical University), G. Wang(Wenzhou Medical University), Tianpei Hong(Peking University), H. Zhang(Capital Medical University), June Liu(Capital Medical University), Yuan Xu(Tongji Hospital)
Diabetes & Metabolism
May 10, 2016
10.1016/j.diabet.2016.04.005
Cited by 21

Related Papers

Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma
|Molecular Cancer|2024|309
Reduced Macrophage Apoptosis Is Associated With Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor-Null Mice
|Arteriosclerosis Thrombosis and Vascular Biology|2004|219
Regulation of seminiferous tubule-associated stem Leydig cells in adult rat testes
|Proceedings of the National Academy of Sciences|2016|149
Perceptions of supportive communication in Chinese patients with cancer: experiences and expectations
|Journal of Advanced Nursing|2005|147
Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner
|American Journal of Physiology-Endocrinology and Metabolism|2016|133